Press Room


    Press Release - September 10, 2007

    Sertoli Cells Successfully Engineered to Secrete Insulin and are Effective in Preclinical Models of Diabetes

    Kelowna, British Columbia - September 10, 2007 - Sernova Corp. (TSX-V: SVA) would like to congratulate Dr. Jannette Dufour and Ms. Katie Halley who have reversed diabetes in an animal model by genetically engineering Sertoli cells to secrete insulin. Sernova owns the exclusive patent rights for the therapeutic use of Sertoli cells to treat diseases including diabetes. These results support the concept that Sertoli cells could be an "implanted drug factory" for numerous disease applications.

    "Dr. Dufour's research is an important finding for the future treatment of diabetes, and other diseases caused by a deficiency in a hormone, protein, or enzyme, because it appears Sertoli cells can be made to secrete any number of therapeutic factors," commented Dr. David White, Sernova's Principal Researcher. "We know from our studies that the immunoprotective properties of Sertoli cells make them ideal candidates for a drug delivery system that can be transplanted without the need for anti- rejection drugs."

    Stated Justin Leushner, Sernova's CEO, "These findings demonstrate the versatility of our Sertoli technology which has been protected in Sernova's many worldwide patents and patent applications. Our core Sertolin�¢ program of using Sertoli cells in combination with islet cells as a treatment for diabetes is continuing. Concurrently we will explore the possibilities for developing therapeutic applications based on these exciting results."

    Dr. Dufour, who is a member of Sernova's Scientific Advisory Board and is on faculty at Texas Tech University Health Sciences Center, will present the study at the joint conference of the Cell Transplant Society, International Pancreas and Islet Transplant Association, and International Xenotransplantation Association being held in Minneapolis on September 15 - 20, 2007.

    About Sernova

    Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies and is currently working on a novel treatment for insulin-dependent diabetes using its patented Sertolin� cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $25 billion annually.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News